SAGA inks deal with Center for Molecular Diagnostics for lung cancer and leukemia tests
LUND, Sweden — /June 14, 2018/ — SAGA Diagnostics AB, a genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients using a simple blood sample, today announces it has entered a customer agreement with the Center for Molecular Diagnostics, Region Skåne, part of the Skåne University Hospital system serving the southern healthcare region of Sweden. As part of the deal, SAGA will deploy its proprietary technology within the laboratories of the Center for Molecular Diagnostics, who will then validate SAGA’s tests for clinical use to aid treatment decisions for patients with non-small lung cancer (NSCLC) and acute myeloid leukemia (AML).
“We are pleased that a major healthcare provider in Sweden appreciates the potential benefits that SAGA’s technology can bring to patients. This first healthcare deal represents an important verification of SAGA’s platform, and adds to our growing success with biopharma customers,” says Åke Nilsson, Director of Corporate and Business Development at SAGA Diagnostics.
Lung cancer (1.2 million new diagnoses per year worldwide) and acute myeloid leukemia (350,000 new diagnoses per year worldwide) are two diseases with increasing need for ultrasensitive diagnostics to monitor patients and identify DNA mutations that can help determine optimal therapy choice.
“SAGA’s tests for mutations in genes such as EGFR and NPM1 could have immediate clinical impact based on what is already known about these important biomarkers,” says SAGA CEO Lao Saal.
Contact: CEO Lao Saal, M.D. Ph.D. firstname.lastname@example.org Phone: +46 (0)70 – 888 52 61
About SAGA Diagnostics
SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using these proprietary technologies gives SAGA unique ultrasensitivity, and gives patients peace of mind.